Risk factor
High price volatility
Profitability factor
Favourable analyst view
About
Implantica AG, a medical technology firm established in 2015 and based in Vaduz, Liechtenstein, specializes in the research, development, and commercialization of advanced medical implants. The company focuses on addressing critical, unmet medical needs, primarily conducting its operations and sales in Switzerland. Its flagship offering is RefluxStop, a CE-marked, passive implant designed for the effective prevention of gastroesophageal reflux disease. Implantica is also actively developing a range of other innovative solutions, including e-InVivo, an internal sensor implant capable of monitoring a wide array of health parameters, providing diagnostic data, and facilitating in-body treatment control. The company is also developing a proprietary wireless energizing platform, which serves as a foundation for several remote-controlled devices. These include AppetiteControl, an implant designed to manage obesity by regulating appetite; UriControl, a remote-activated implant for treating urinary incontinence in both men and women; and UriRestor, a remote-controlled device leveraging the wireless platform to enable individuals with spinal cord injuries and multiple sclerosis to urinate on demand. Implantica AG operates as a subsidiary of Implantica MediSwiss.
Company Valuation
Based on key historical and expected multiples, the stock is overvalued relative to its peers.
Target Price
The average target price of IMP-A-SDB.ST is 90.8 and suggests 45% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation t